PDCs have gained extensive attention as they are being proven successful in treating cancers recently with their superior target-specific delivery. PDCs combine peptides and linker-toxins, their development and manufacturing require comprehensive synthetic chemistry, process development, analytical method development, and manufacturing capabilities for both highly potent small molecules and peptides, which often bring technical challenges, especially during scale-up. Here we discuss how we overcome challenges and demonstrate opportunities through case studies.